SEC Filing | argenx
Argenx gets FDA nod for first subcutaneous gMG therapy | pharmaphorum
ITP Support Association - Press release from argenx, they are evaluating: Efgartigimod in ITP: Phase 3 ADVANCE registrational trial initiated evaluating approximately 150 primary ITP patients dosed with 10mg/kg IV efgartigimod for
Latest Healthcare and Pharma Press Release | Latest Healthcare News
argenx SE (ARGX) Stock Price, Quote & News - Stock Analysis
SEC Filing | argenx
Corporate Presentation June 2023
FUJIFILM Diosynth Biotechnologies enters into an Agreement with Argenx
ELITE 2023 Marketing Team VYVGART Brand Launch Team of argenx | PM360
argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience
argenx | News
argenx on X: "Today we announced the continuation of our chronic inflammatory demyelinating polyneuropathy (CIDP) program following interim analysis of the Phase 2/3 ADHERE trial. Learn more here: https://t.co/0vgXZk0o0u https://t.co/iv5KRcJfH8" / X
ARGENX SE - VYVGART for Generalized Myasthenia Gravis VYVGART and VYVGART Hytrulo are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
ARGENX SE Form 6-K Current Report Filed 2023-01-09
Argenx's Potential Blockbuster Gets FDA Nod for Autoimmune Disease
Myasthenia Gravis Foundation of America, Inc. - argenx announces positive topline results from Phase 3 ADAPT trial for gMG. ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia
argenx | News
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
argenx Receives the EMA's CHMP Positive Opinion of Efgartigimod for Generalized Myasthenia Gravis
Argenx Files for FDA Approval of Efgartigimod for Generalized MG
Genmab expands immunology reach in argenx pact
Press Releases | Argenx
argenx | News
